Future diagnostic and therapeutic trends in endocrine cancers

Allen M. Spiegel, Steven K. Libutti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current treatment of endocrine cancers relies primarily on surgical resection, which is generally effective only for localized disease. Radioactive iodine treatment is an important modality for those thyroid cancers that maintain the ability to take up iodine. For endocrine cancers that are no longer localized, current modes of therapy, including various combinations of chemotherapy and radiation, are inadequate, posing a major challenge to ongoing research to develop more effective methods for diagnosis and treatment. In this article, we offer some predictions of future trends in the diagnosis and treatment of endocrine cancers. Following a general introduction, we focus on thyroid cancer as a paradigm for what we may expect in future developments, and then add selected comments relevant to parathyroid, adrenocortical, and gastrointestinal and pancreatic neuroendocrine tumors. Rapid, inexpensive whole genome sequencing of both germline and tumor DNA, novel molecular and functional imaging, as well as new biomarkers are expected to enable more precise diagnosis, targeted therapy, and possibly prevention. Translating the coming wave of data on the molecular pathogenesis of endocrine cancers into practical diagnostic and treatment modalities will require new forms of collaboration between investigators, clinicians, and industry.

Original languageEnglish (US)
Pages (from-to)691-695
Number of pages5
JournalSeminars in oncology
Volume37
Issue number6
DOIs
StatePublished - Dec 1 2010

Fingerprint

Endocrine Gland Neoplasms
Thyroid Neoplasms
Iodine
Therapeutics
Molecular Imaging
Neuroendocrine Tumors
Combination Drug Therapy
Industry
Biomarkers
Research Personnel
Genome
Radiation
DNA

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{66cead2175394af79caf7070fe0be61e,
title = "Future diagnostic and therapeutic trends in endocrine cancers",
abstract = "Current treatment of endocrine cancers relies primarily on surgical resection, which is generally effective only for localized disease. Radioactive iodine treatment is an important modality for those thyroid cancers that maintain the ability to take up iodine. For endocrine cancers that are no longer localized, current modes of therapy, including various combinations of chemotherapy and radiation, are inadequate, posing a major challenge to ongoing research to develop more effective methods for diagnosis and treatment. In this article, we offer some predictions of future trends in the diagnosis and treatment of endocrine cancers. Following a general introduction, we focus on thyroid cancer as a paradigm for what we may expect in future developments, and then add selected comments relevant to parathyroid, adrenocortical, and gastrointestinal and pancreatic neuroendocrine tumors. Rapid, inexpensive whole genome sequencing of both germline and tumor DNA, novel molecular and functional imaging, as well as new biomarkers are expected to enable more precise diagnosis, targeted therapy, and possibly prevention. Translating the coming wave of data on the molecular pathogenesis of endocrine cancers into practical diagnostic and treatment modalities will require new forms of collaboration between investigators, clinicians, and industry.",
author = "Spiegel, {Allen M.} and Libutti, {Steven K.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1053/j.seminoncol.2010.10.020",
language = "English (US)",
volume = "37",
pages = "691--695",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Future diagnostic and therapeutic trends in endocrine cancers. / Spiegel, Allen M.; Libutti, Steven K.

In: Seminars in oncology, Vol. 37, No. 6, 01.12.2010, p. 691-695.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Future diagnostic and therapeutic trends in endocrine cancers

AU - Spiegel, Allen M.

AU - Libutti, Steven K.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Current treatment of endocrine cancers relies primarily on surgical resection, which is generally effective only for localized disease. Radioactive iodine treatment is an important modality for those thyroid cancers that maintain the ability to take up iodine. For endocrine cancers that are no longer localized, current modes of therapy, including various combinations of chemotherapy and radiation, are inadequate, posing a major challenge to ongoing research to develop more effective methods for diagnosis and treatment. In this article, we offer some predictions of future trends in the diagnosis and treatment of endocrine cancers. Following a general introduction, we focus on thyroid cancer as a paradigm for what we may expect in future developments, and then add selected comments relevant to parathyroid, adrenocortical, and gastrointestinal and pancreatic neuroendocrine tumors. Rapid, inexpensive whole genome sequencing of both germline and tumor DNA, novel molecular and functional imaging, as well as new biomarkers are expected to enable more precise diagnosis, targeted therapy, and possibly prevention. Translating the coming wave of data on the molecular pathogenesis of endocrine cancers into practical diagnostic and treatment modalities will require new forms of collaboration between investigators, clinicians, and industry.

AB - Current treatment of endocrine cancers relies primarily on surgical resection, which is generally effective only for localized disease. Radioactive iodine treatment is an important modality for those thyroid cancers that maintain the ability to take up iodine. For endocrine cancers that are no longer localized, current modes of therapy, including various combinations of chemotherapy and radiation, are inadequate, posing a major challenge to ongoing research to develop more effective methods for diagnosis and treatment. In this article, we offer some predictions of future trends in the diagnosis and treatment of endocrine cancers. Following a general introduction, we focus on thyroid cancer as a paradigm for what we may expect in future developments, and then add selected comments relevant to parathyroid, adrenocortical, and gastrointestinal and pancreatic neuroendocrine tumors. Rapid, inexpensive whole genome sequencing of both germline and tumor DNA, novel molecular and functional imaging, as well as new biomarkers are expected to enable more precise diagnosis, targeted therapy, and possibly prevention. Translating the coming wave of data on the molecular pathogenesis of endocrine cancers into practical diagnostic and treatment modalities will require new forms of collaboration between investigators, clinicians, and industry.

UR - http://www.scopus.com/inward/record.url?scp=78650249648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650249648&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2010.10.020

DO - 10.1053/j.seminoncol.2010.10.020

M3 - Article

C2 - 21167386

AN - SCOPUS:78650249648

VL - 37

SP - 691

EP - 695

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -